Events & Opportunities

Breast Cancer Biology, Technology, and Commercialization: A Bench to Bedside to Market Translational Story

October 26, 2020 | 1:00 PM - 2:00 PM

Presented by Yale Alumni Health Network with support from Komen Philadelphia and the University of Pennsylvania.

Register here now, then invite others to join you.

  • This is a free online event held via the Zoom meeting platform
  • Registration is required*

*By registering for this webinar, you agree to share your email address with these groups: Yale Alumni Health Network, University of Pennsylvania, Susan G. Komen Philadelphia, YaleWomen, and the Yale Alumni Association Shared Interest Groups.

Seminar focus: Using new biological discoveries and technology to diagnose and treat recurrent breast cancer early and effectively.

Biomedical research drives an increasingly individualized approach to cancer treatment, known as “precision oncology” for many cancers including breast cancer. While detection and increasingly effective treatments have lowered breast cancer mortality, women are still dying of recurrent metastatic breast cancer. Bringing scientific discoveries to the patient requires a bridge between biologic science, engineering, and business to guide new science from the bench to the clinic, and into a sustainable commercial platform. 

In this engagement, you will learn from three Yale alumni—all in our local community—who will share how they have used their Yale background in molecular biology, physics, and economics to bring novel biology and technology to breast cancer patients and to industry. With a vision of emphasizing the translational process and the multi-disciplinary skillsets needed to navigate the pathway from the bench to the clinic, the session will discuss the progress being made in:

  • Understanding the biology of breast cancer recurrence after treatment and developing novel diagnostics to detect dormant breast cancer cells that lead to recurrence
  • Using molecular imaging to diagnose recurrent breast cancer and directed targeted treatment
  • Commercializing new imaging drugs with the goal of FDA approval and widespread clinical availability

Our expert, and accomplished, discussion leaders

Jean Cho, MBA, Trevarx Biomedical, Inc.
Co-founder, CEO
Yale class of 1982 

Lewis Chodosh, MD, PhD, University of Pennsylvania
Perelman Professor; Chairman, Department of Cancer Biology; Associate Director for Basic Science, Penn Medicine's Abramson Cancer Center
Yale class of 1981

David Mankoff, MD, PhD, University of Pennsylvania
Gerd Muehllehner Professor; Vice-chair for Research, Department of Radiology; Associate Director for Education and Training, Penn Medicine's Abramson Cancer Center
Yale class of 1981

In addition, our discussion will  feature welcoming remarks from:

  • Dr. Jamie Wells, Yale class of 1996 and Chair of the Yale Alumni Health Network: Adjunct Professor at Drexel University’s School of Biomedical Engineering, Science and Health Systems
  • Jennifer Ebisemiju Madar, Yale class of 1988: Internal Communications Consultant, Wayfair
  • Elaine I. Grobman: CEO Susan G. Komen Philadelphia


Presenter Bios

Jean Cho, MBA, Trevarx Biomedical, Inc.
Prior to founding Trevarx, Ms. Cho has led marketing, product planning and strategy groups at the Office, E-Commerce and Consumer Divisions of Microsoft Corporation and was vice-president in Corporate Finance at Drexel Burnham Lambert. She has an MBA from Harvard Business School but always roots for Yale at The Game.


Lewis Chodosh, MD, PhD, University of Pennsylvania
Perelman Professor and Chairman of the Department of Cancer Biology at the University of Pennsylvania, Dr. Chodosh  also serves as Associate Director for Basic Science for Penn’s Abramson Cancer Center.  His research focus is on understanding why some breast cancers recur and on the mechanisms that enable cancer cells to exist in a ‘dormant’ state prior to their recurrence.  Through the 2-PREVENT Translational Center of Excellence that he co-Directs, Dr. Chodosh has been working to translate that information to the clinic by developing improved methods for detecting and eradicating dormant cancer cells that survive therapy in order to prevent metastatic breast cancer recurrence.

David Mankoff, MD, PhD, University of Pennsylvania
The Gerd Muehllehner Professor and Vice-Chair for Research in the Department of Radiology at the University of Pennsylvania, Dr. Mankoff  also serves as Associate Director for Education and Training for Penn’s Abramson Cancer Center.  His research centers on the application of positron emission tomography (PET) to cancer with a focus on breast cancer and guiding targeted cancer treatments. In addition to his translational and clinical research, Dr. Mankoff has been involved in the commercialization of PET scanners and PET imaging drugs.  Dr. Mankoff is a Susan G. Komen Scholar and works closely with Susan G. Komen Philadelphia to empower the fight in our local community.


Registration, information, action!

  • Sign up for this experience here. Registration is free and required to receive access to our Zoom Room for October 26.
  • Share this page/event information and invite others in your breast cancer network.
  • Follow us on FacebookInstagram and Twitter for more news, updates and opportunities.
Newsletter Add your email to stay informed